Evidence map›Paper›PMID 39589189›Full record

ArticleAmerican journal of physiology. Renal physiology2025

Transcriptomics of SGLT2-positive early proximal tubule segments in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.

Young Chul Kim, Vivek Das, Sadhana Kanoo, Huazhen Yao, Stephanie M Stanford, Nunzio Bottini, Anil Karihaloo, Volker Vallon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Renal physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Laser capture microdissection.Nature reviews. Methods primers · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Young Chul KimDivision of Nephrology & Hypertension, Department of Medicine, University of California San Diego, La Jolla, California, United States.ORCID 0000-0002-6782-2186
Vivek DasNovo Nordisk A/S, Søborg, Denmark.ORCID 0000-0003-0614-0373
Sadhana KanooDivision of Nephrology & Hypertension, Department of Medicine, University of California San Diego, La Jolla, California, United States.
Huazhen YaoInstitute for Genomic Medicine, University of California San Diego, La Jolla, California, United States.
Stephanie M StanfordDivision of Rheumatology, Allergy & Immunology, Department of Medicine, University of California San Diego, La Jolla, California, United States.
Nunzio BottiniDivision of Rheumatology, Allergy & Immunology, Department of Medicine, University of California San Diego, La Jolla, California, United States.ORCID 0000-0001-9025-7501
Anil KarihalooNovo Nordisk, Lexington, Massachusetts, United States.
Volker VallonDivision of Nephrology & Hypertension, Department of Medicine, University of California San Diego, La Jolla, California, United States.ORCID 0000-0002-9211-2063

Funding

UAB-UCSD O'Brien Center for Acute Kidney Injury ResearchU54DK137307 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PAUL W. SANDERS · 2023 to 2026
$4.4M
Glomerular and Tubular Function in the Diabetic KidneyR01DK112042 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI SCOTT Culver THOMSON, Volker Vallon · 2017 to 2026
$4.1M
Resource-based Center for the study of the joint microenvironment in rheumatology (Overall Application)P30AR073761 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CORR, MARY P · 2018 to 2022
$3.9M
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) P30AR073761HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK112042HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U54DK137307NIAMS NIH HHS P30 AR073761NIDDK NIH HHS R01 DK112042NIDDK NIH HHS U54 DK137307NIH HHS S10 OD026929Novo Nordisk (Novo Nordisk Global)ODCDC CDC HHS S10 OD026929
6 · The paper itself

Abstract

SGLT2 inhibitors (SGLT2i) and GLP1 receptor (GLP1R) agonists have kidney protective effects. To better understand their molecular effects, RNA sequencing was performed in SGLT2-positive proximal tubule segments isolated by immunostaining-guided laser capture microdissection. Male adult DBA wild-type (WT) and littermate diabetic Akita mice ±

Indexed as

Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsKidney Tubules, ProximalMice, KnockoutSodium-Glucose Transporter 1Sodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsTranscriptomeAnimalsBenzhydryl CompoundsBlood GlucoseDiabetes Mellitus, Type 1Gene Expression ProfilingGlucosidesMaleMiceBenzhydryl CompoundsBlood GlucosedapagliflozinGlp1r protein, mouseGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlucosidesSlc5a1 protein, mouseSlc5a2 protein, mouseSodium-Glucose Transporter 1Sodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorsglucagon-like peptide-1 receptor agonistlaser capture microdissectionproximal tubuleRNA-seqSGLT2 inhibitor

Identifiers

PMID39589189
PMCPMC11918450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.